It was a beautiful event on May 6 at Schloss Au. Redbiotec is very proud and honored of the nearly 100 guests attending the anniversary party in the wonderful Schloss Au right next to the Lake of Zurich. We see this as a proof of the continued high interest in Redbiotec and the big commitment. Some impressions:
We would like to thank all our investors, clients, partners, advisors, suppliers for the successful collaboration in the last ten years – and especially acknowledge all our former and current employees!
Redbiotec is pleased to announce the appointment of Prof. Dr. Yaakov (Kobi) Benenson, Professor of Synthetic Biology at ETH Zurich, to its team. Prof. Benenson is best known for his work on biomolecular computing circuits. MIT Technology Review named him one of the world’s top 100 young innovators in 2004. Prof. Benenson will reinforce Redbiotec’s activities in engineering bacteria for cancer therapies and diagnostics.
Redbiotec announces today the appointment of Research Associate Professor Sita Awasthi from the University of Pennsylvania,Infectious Disease Division, Perelman School of Medicine, to its team. Sita Awasthi is a leading expert in vaccine development and immunology of infectious diseases, and will support Redbiotec in its Herpes Simplex Virus vaccine program.
Redbiotec has filed a new patent application covering its novel antigens against Herpes simplex viruses. The antigens developed by Redbiotec comprise potent trimers and dimers as well as combinations thereof. Redbiotec expects first results from its ongoing in vitro and in vivo studies by Q2 2016.
Redbiotec will attend JPM 34th Healthcare Conference in San Francisco starting January 11 2016. Redbiotec’s delegation will include the two projects leaders of Redbiotec’s HSV-2 vaccine and Universal Flu vaccine programs.